SynVaccine
David Zigdon serves as CEO of MIGAL Galilee Research Institute and President of MigVax, while also holding multiple board member positions at organizations including BELKIN Laser Ltd., Moebius Medical Ltd., and Vascular Graft Solutions. Since January 2019, David has been a member of the Board of Advisors for Zigdon Enterprises. Previous board memberships include ProJini, Everads Therapy Ltd., Perflow Medical, and Radiaction Ltd., showcasing extensive leadership in the medical and technology sectors. David holds a BA in Economic and Accounting and an LLM in Law from Bar-Ilan University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
SynVaccine
SynVaccine develops preventive viral vaccines for various major human pathogens. It owns licenses for disruptive technologies that enable the computational rational design of viral genomes and physical DNA editing of viral vaccine genome libraries. Tuval Ben Yehezkel founded SynVaccine in 2013. It has its headquarters in Tel Aviv in Israel.